Nautilus Biotechnology, Inc. (NAUT)
After hours:
| Previous Close | 2.3600 |
| Open | 2.4200 |
| Bid | 2.4000 x 100 |
| Ask | 2.5700 x 100 |
| Day's Range | 2.3508 - 2.5100 |
| 52 Week Range | 2.1600 - 4.6500 |
| Volume | |
| Avg. Volume | 77,580 |
| Market Cap | 311.494M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings Date | Apr 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
GlobeNewswireNautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of th
Simply Wall St.This Nautilus Biotechnology Insider Increased Their Holding In The Last Year
Looking at Nautilus Biotechnology, Inc.'s ( NASDAQ:NAUT ) insider transactions over the last year, we can see that...
- GlobeNewswire
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. “2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform”, said Suj
